NCT05812976Completed
Novel Index (PIMR) in PAH
Impact of the Pulmonary Index of Microcirculatory Resistance in Pulmonary Arterial Hypertension
Source: ClinicalTrials.gov · Last updated 1 Aug 2025
Brief summary (registry, in English)
The chief regulator of resistance in pulmonary arterial hypertension (PAH) is the small arteries. In the heart, the invasive measurement of the resistance of the small arteries has been shownto be safe, easy, reliable, and prognostic. This study is intended to translate prior work in heart arteries to the PAH space and invasively measure the resistance of the small arteries of the lung (pulmonary index of microcirculatory resistance \[PIMR\]) and the coronary artery supplying the right ventricle (acute marginal of the RCA; RV-IMR). Importantly, these measurements will be made during standard of care cardiac catheterizations (right heart catheterization \[RHC\] +/- left heart catheterization). The correlation between these new indices and the standard ones measured during RHC typically used to determine the severity of pulmonary hypertension will be analyzed. In addition, among newly diagnosed patients, the study will evaluate how these indices change 6 months after starting treatment. Finally, the association of these indices with clinical outcomes at 1 year will be assessed. The findings from this study may deliver an immediate impact to patient care by identifying a new metric to help better identify those who may benefit from a more intensive, personalized treatment regimen.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 22 (actual)
- First submitted
- 1 Apr 2023
- Start date
- 1 Feb 2023
- Primary completion date
- 8 Apr 2025
- Lead sponsor
- University of California, Los Angeles
- NCT number
- NCT05812976
What you commit to
- Study type: Observational
- Participants enrolled: 22
- From 1 Feb 2023 to the primary completion date, 8 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other groups/forms of pulmonary hypertension (i.e. groups 2-5)
Other
- Contraindicated to undergo fluoroscopy and/or coronary angiography
- Pregnancy
Who the study is looking for
- Diagnosis of Group 1 PAH with invasive pulmonary hypertension defined as: Mean pulmonary arterial pressure ≥ 20 mmHg, pulmonary capillary wedge pressure \< 15 mmHg, and pulmonary vascular resistance ≥ 3 Wood units.
- Serum creatinine \< 2.0 mg/dL
- Able to provide informed written consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ronald Reagan UCLA Medical Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.